Location History:
- Shanghai, CN (2011 - 2012)
- Basel, CH (2014)
Company Filing History:
Years Active: 2011-2014
Title: The Innovative Contributions of Rainer Hillenbrand
Introduction
Rainer Hillenbrand, an accomplished inventor located in Shanghai, China, has made significant strides in the field of biotechnology. With three patents to his name, his work primarily focuses on the development of high-specificity antibodies and drug monitoring assays. His innovative contributions showcase the intersection of science and practical applications in medicine.
Latest Patents
Rainer's latest patents highlight his expertise in antibody engineering and drug monitoring techniques. One significant patent involves the creation of antibodies that can distinguish between modified human IGF-1/E peptides and the endogenous wild-type human IGF-1 proteins. These high-specificity antibodies demonstrate minimal cross-reactivity with other relevant proteins, aiding in pharmacokinetic and pharmacodynamic assessments in both human and animal subjects. This innovation is crucial for accurate quantification using a sandwich ELISA assay to measure mutant IGF-1/E proteins in samples.
Another notable patent details a method for obtaining binding agents that interact with pharmaceutically active compounds with greater specificity than their inactive counterparts. This breakthrough not only involves the development of these binding agents and their derivatives but also highlights their utilization in drug monitoring assays, fostering advancements in pharmaceutical applications.
Career Highlights
Rainer Hillenbrand currently works for Novartis AG, a leading global healthcare company. His role at Novartis allows him to further his research and development efforts, contributing to cutting-edge advancements in the field. His innovative work continues to impact the medical industry significantly, particularly in drug development and therapeutic assessments.
Collaborations
Throughout his career, Rainer has collaborated with several skilled professionals in his industry, including Francois Legay and Patrick Albientz. These collaborations not only enhance the quality of his inventions but also foster an environment of innovation within the scientific community.
Conclusion
Rainer Hillenbrand is a remarkable inventor whose work in antibodies and drug monitoring assays is paving the way for future innovations in biotechnology and pharmaceuticals. His contributions at Novartis AG and his collaborative efforts with esteemed colleagues underline the importance of teamwork in driving advancements in science and medicine. Rainer’s continued research promises to have a lasting impact on the field, ultimately benefiting countless individuals across the globe.